Literature DB >> 27125804

Using opioids in general practice for chronic non-cancer pain: an overview of current evidence.

David C Currow1, Jane Phillips2, Katherine Clark3.   

Abstract

Chronic non-cancer pain (lasting more than 3 months) is highly prevalent in Australia (17% of males and 20% of females) and its optimal management is crucial to the health and wellbeing of the community. For 5% of the population, such pain interferes markedly with daily function. Part of the treatment for acute non-cancer pain for many people will include opioid analgesics at least for days to weeks. However, as pain becomes chronic, evidence to support ongoing prescription of opioids is lacking. There is increasing pressure to ensure that prescribing opioid analgesics is minimised to reduce not only the risk of dependence and illicit diversion but also the potential harms associated with tolerance, side effects and complications. Frameworks for considering opioid prescribing include assessing suitability of the patient for opioids; initiating a trial of therapy; and monitoring long term use. There is limited evidence of the long term efficacy of opioids for chronic non-cancer pain, and documented clinical consequences beyond addiction include acceleration of loss of bone mineral density, hypogonadism and an association with increased risk of acute myocardial infarction. Careful clinical selection of patients can help optimise the evidence-based use of opioids for chronic non-cancer pain: only treat pain that has been as well defined as possible when non-opioid therapies have not been effective; consider referral to specialist services for assessment if doses are above 100 mg oral morphine equivalent per 24 hours or the duration of therapy is longer than 4 weeks; limit prescribing to only one practitioner; seek an agreement with the patient for the initiation and potential withdrawal of opioids if the therapeutic trial is not effective.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27125804     DOI: 10.5694/mja16.00066

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  10 in total

1.  A population-based study of transdermal fentanyl initiation in Australian clinical practice.

Authors:  Natasa Gisev; Sallie-Anne Pearson; Briony Larance; Sarah Larney; Bianca Blanch; Louisa Degenhardt
Journal:  Eur J Clin Pharmacol       Date:  2018-11-03       Impact factor: 2.953

2.  Analysis of inflammation-induced depression of home cage wheel running in rats reveals the difference between opioid antinociception and restoration of function.

Authors:  Ram Kandasamy; Jonas J Calsbeek; Michael M Morgan
Journal:  Behav Brain Res       Date:  2016-10-13       Impact factor: 3.332

3.  Role of Rehabilitation in Opioid Tapering: A Scoping Review.

Authors:  Miranda Wiens; Devon Jarrett; Alissa Settimi; Courtney White; Zachary Hollingham; Tara Packham
Journal:  Physiother Can       Date:  2021-06-07       Impact factor: 1.037

4.  Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.

Authors:  Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson
Journal:  CMAJ       Date:  2018-03-26       Impact factor: 8.262

5.  Morphine dependence is attenuated by red ginseng extract and ginsenosides Rh2, Rg3, and compound K.

Authors:  Taddesse Yayeh; Kyunghwa Yun; Soyong Jang; Seikwan Oh
Journal:  J Ginseng Res       Date:  2016-08-21       Impact factor: 6.060

6.  Use of Opioids Increases With Age in Older Adults: An Observational Study (2005-2017).

Authors:  Yvette M Weesie; Karin Hek; Tjard R J Schermer; Francois G Schellevis; Hubertus G M Leufkens; Elisabeth J Rook; Liset van Dijk
Journal:  Front Pharmacol       Date:  2020-05-14       Impact factor: 5.810

Review 7.  Can a power law improve prediction of pain recovery trajectory?

Authors:  George C Hartmann; Steven Z George
Journal:  Pain Rep       Date:  2018-06-13

8.  Patterns of opioid use (codeine, morphine or meperidine) in the Canadian population over time: analysis of the Longitudinal National Population Health Survey 1994-2011.

Authors:  Mayilee Canizares; J Denise Power; Y Raja Rampersaud; Elizabeth M Badley
Journal:  BMJ Open       Date:  2019-07-24       Impact factor: 2.692

9.  A comparison of opioids and benzodiazepines dispensing in Australia.

Authors:  M Mofizul Islam; Dennis Wollersheim
Journal:  PLoS One       Date:  2019-08-19       Impact factor: 3.240

10.  Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain.

Authors:  Javier Rejas-Gutierrez; Antoni Sicras-Mainar; Josep Darbà
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-04-29       Impact factor: 5.346

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.